Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 511 clinical trials
FT516 in Subjects With Advanced Hematologic Malignancies

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

leukemia
b-cell lymphoma
antibody therapy
lymphoma
monoclonal antibodies
  • 19 views
  • 04 Oct, 2022
  • 7 locations
Ruxolitinib and Decitabine for High Risk Hematological Malignancies

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing

  • 0 views
  • 25 Jan, 2021
  • 1 location
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study …

direct bilirubin
ruxolitinib
thrombocytopenia
polycythemia
chronic myelomonocytic leukemia
  • 14 views
  • 25 May, 2022
  • 1 location
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic

leukemia
b-cell lymphoma
oxygen saturation
follicular lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 01 Sep, 2021
  • 1 location
A Study of TQB3820 in Patients With Hematological Malignancies

TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects …

multiple myeloma
measurable disease
  • 0 views
  • 27 Sep, 2021
  • 2 locations
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood cancer). This study will

lymphoma
myelodysplastic syndromes
IDH2
induction chemotherapy
refractory acute myeloid leukemia (aml)
  • 0 views
  • 06 Dec, 2021
  • 2 locations
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the …

leukemia
graft versus host disease
lymphoma
fludarabine
philadelphia chromosome
  • 17 views
  • 12 Mar, 2022
  • 1 location
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I-II)

This is a Phase I-II, multi-center, open-label, FIH study comprising of 3 study parts (Phase Ia, Phase Ib, and Phase II). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects …

leukemia
lymphoma
follicular lymphoma
chronic lymphocytic leukemia
b-cell small lymphocytic lymphoma
  • 19 views
  • 08 Dec, 2021
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET

The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).

multiple myeloma
lymphoma
measurable disease
  • 0 views
  • 13 May, 2022
  • 1 location
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies

This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.

blast crisis
leukemia
myelomonocytic leukemia
cell transplantation
hydroxyurea
  • 17 views
  • 13 Oct, 2022
  • 3 locations